Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) jumped $6.43 (45%) to $20.70 on NASDAQ on Friday after announcing post-market on Thursday that FDA converted its full clinical hold on a Phase I trial of the company's TKM-Ebola to a partial hold. Tekmira ended the week up 45%, for a market cap gain of $142.2 million to $457 million.

The Tekmira news appeared to buoy shares of other publicly traded biotechs with Ebola candidates. Sarepta Therapeutics Inc. (NASDAQ:SRPT) gained $1.20 (6%) to